Remibrutinib Doubles Complete-Response Rates in Phase 3 CIndU Trial

A complete response rate of 56.3% in cold urticaria — more than three times the placebo rate — stands as the headline result of the phase 3 remIND study of remibrutinib in chronic inducible urticaria (CIndU), a condition for which no FDA-approved therapy exists. In a Dermatology Times Between the Lines series, moderator Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, reviewed the trial's design, efficacy, and safety, along with the treatment gap the data may begin to close.

How large is the CIndU burden?

CIndU comprises distinct subtypes in which specific stimuli provoke wheals, angioedema, or both. Finklea estimated global prevalence at approximately 0.5% to 1.5%, with symptomatic dermatographism (wheals provoked by mechanical rubbing of the skin) accounting for roughly half of cases. Cold and cholinergic urticaria follow in frequency; solar, heat, aquagenic, vibratory, contact, and delayed pressure urticaria occur less often.

The panel cautioned that diagnosis frequently begins too late. Patients may live for years with symptoms that interfere with work and recreation, and the disease burden is easy to underestimate because patients reorganize their lives around trigger avoidance. Both clinicians urged asking not only about hives but also about how the disease shapes daily activities.

Standardized provocation testing can strengthen diagnosis. The FricTest (a standardized instrument for stroking the skin) and temperature testing allow clinicians to characterize disease objectively and track response to therapy — a point that becomes central to interpreting remIND itself.

Why do antihistamines fall short?

Second-generation H1 antihistamines remain first-line therapy, yet Finklea cited standard-dose efficacy in only approximately 20% to 50% of patients. Even after up-titration, a substantial proportion remain inadequately controlled. She described a methodical approach: increasing the dose over approximately 2 to 3 weeks while setting expectations with patients, and stressing daily preventive dosing rather than waiting for symptoms to appear.

Once patients fail higher-dose antihistamines, the gap widens. With no FDA-approved medication specifically for CIndU at the time of the discussion, clinicians have largely extrapolated strategies from chronic spontaneous urticaria (CSU), a related condition without an external trigger.

What does BTK inhibition add?

The pathophysiology of CIndU is not fully elucidated, but mast cell activation appears central. Finklea explained that multiple immune pathways involved in mast cell activation converge on Bruton tyrosine kinase (BTK), a signaling molecule downstream of the high-affinity IgE receptor. Remibrutinib, a highly selective BTK inhibitor, is intended to block mast cell degranulation and the subsequent release of histamine and inflammatory mediators.

That mechanism provided the rationale for testing the drug across three clinically distinct populations in remIND: symptomatic dermatographism, cold urticaria, and cholinergic urticaria.

What did remIND show?

The study (NCT05276243 registered as NCT05976243) enrolled adults with CIndU who remained symptomatic despite background second-generation H1 antihistamines. Participants received remibrutinib 25 mg twice daily or placebo, with the primary end point assessed at week 12 using subtype-specific provocation testing: FricTest for symptomatic dermatographism, temperature testing for cold urticaria, and an exercise provocation test for cholinergic urticaria.

The end point was deliberately demanding. Patients had to demonstrate no elicited hives following provocation — not merely improvement.

• Symptomatic dermatographism: approximately 29% complete response, roughly twice placebo.
• Cholinergic urticaria: approximately 29% complete response, roughly twice placebo.
• Cold urticaria: 56.3% complete response, more than three times placebo.

For symptomatic dermatographism, complete response meant moving from substantial baseline disease activity to a FricTest score of 0, with no elicited wheal. Responses also emerged quickly: significant differences in symptomatic dermatographism were evident by week 2 and persisted through weeks 12 and 24. The experts cautioned that longer-term follow-up will determine whether patients who do not initially achieve complete control continue improving over time.

Is complete response the only measure of success?

The panel debated whether total clearance should define treatment success in practice. A FricTest score of 1 reflects mild disease rather than complete response, and Finklea said she would ideally like every patient to reach 0 but considers 1 a practical goal for many, particularly because disease activity may fluctuate between visits. A patient who misses the strict end point may still gain meaningful improvement in symptoms, daily activities, and quality of life.

What does the safety profile show?

Over the 24-week placebo-controlled period, severe adverse events were comparable between groups and consistent with the larger remibrutinib CSU development program. Most events were mild to moderate, discontinuation rates were low, and no deaths were reported. Events occurring at rates of 5% or greater — respiratory infection, headache, nausea — were similar between groups.

One signal warrants attention. Petechiae (small pinpoint bleeds under the skin) occurred in 5.2% of remibrutinib-treated patients versus 1.8% on placebo, prompting the panel to recommend counseling patients on what to watch for. The experts distinguished remibrutinib's selectivity from the safety profiles of earlier BTK inhibitors developed in hematology and oncology — a manufacturer-aligned framing that lacks head-to-head comparative data.

Where does remibrutinib fit?

The panel placed remibrutinib alongside omalizumab and dupilumab as advanced options. Omalizumab holds the largest body of CIndU literature but carries no CIndU-specific indication; dupilumab evidence remains limited. No head-to-head comparisons exist among these therapies, and treatment decisions will continue to depend on subtype, age, comorbidities, available evidence, and patient preference.

For Finklea, the remIND findings signal a step toward closing a persistent treatment gap, particularly in symptomatic dermatographism. As additional long-term data emerge, the findings may refine treatment guidelines and reshape expectations for what successful CIndU management can look like.